Dohoon Kim

Dr. Dohoon Kim


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
ACAnne E. Carlisle
Anne E. Carlisle
NLNamgyu Lee
Namgyu Lee
AMAsia N. Matthew-Onabanjo
Asia N. Matthew-Onabanjo
MSMeghan E. Spears
Meghan E. Spears
SPSung Jin Park
Sung Jin Park
DKDohoon Kim
Dohoon Kim

20 February 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Namgyu LeeNamgyu Lee
Namgyu Lee
ACAnne E. Carlisle
Anne E. Carlisle
APAustin Peppers
Austin Peppers
SPSung Jin Park
Sung Jin Park
MDMihir Doshi
Mihir Doshi
DKDohoon Kim
Dohoon Kim
Inducers of ferroptosis such as the glutathione depleting agent Erastin and the GPX4 inhibitor Rsl-3 are being actively explored as potential therapeutics in various cancers, but the factors that determine their sensitivity are poorly understood. Here, we show that expression levels of both subunits of the cystine/glutamate antiporter xCT determine the expression of GPX4 in breast cancer, and that upregulation of the xCT/selenocysteine biosynthesis/GPX4 production axis paradoxically renders the cancer cells more sensitive to certain types of ferroptotic stimuli. We find that GPX4 is strongly upregulated in a subset of breast cancer tissues compared to matched normal samples, and that this is tightly correlated with the increased expression of the xCT subunits SLC7A11 and SLC3A2. Erastin depletes levels of the antioxidant selenoproteins GPX4 and GPX1 in breast cancer cells by inhibiting xCT-dependent extracellular reduction which is required for selenium uptake and selenocysteine biosynthesis. Unexpectedly, while breast cancer cells are resistant compared to nontransformed cells against oxidative stress inducing drugs, at the same time they are hypersensitive to lipid peroxidation and ferroptosis induced by Erastin or Rsl-3, indicating that they are ‘addicted’ to the xCT/GPX4 axis. Our findings provide a strategic basis for targeting the anti-ferroptotic machinery of breast cancer cells depending on their xCT status, which can be further explored.

1 December 2016 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
NLNamgyu Lee
Namgyu Lee
DKDohoon Kim
Dohoon Kim
Namgyu Lee, and Dohoon Kim. Mol. Cells 2016;39:847-54. https://doi.org/10.14348/molcells.2016.0310

13 February 2024 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
NLNamgyu Lee
Namgyu Lee
SPSung Jin Park
Sung Jin Park
MLMike Lange
Mike Lange
TTTenzin Tseyang
Tenzin Tseyang
MDMihir Doshi
Mihir Doshi
DKDohoon Kim
Dohoon Kim

25 October 2023 in Nature
Verified
Journal Article
Closed access
PDF file
MDMihir Doshi
Mihir Doshi
NLNamgyu Lee
Namgyu Lee
TTTenzin Tseyang
Tenzin Tseyang
OPOlga Ponomarova
Olga Ponomarova
HGHira Lal Goel
Hira Lal Goel
DKDohoon Kim
Dohoon Kim

24 July 2020 in Oncogene
Verified
Journal Article
Open access
PDF file
NLNamgyu Lee
Namgyu Lee
MSMeghan E. Spears
Meghan E. Spears
ACAnne E. Carlisle
Anne E. Carlisle
DKDohoon Kim
Dohoon Kim
It is well recognized that many metabolic enzymes play essential roles in cancer cells in producing building blocks such as nucleotides, which are required in greater amounts due to their increased proliferation. On the other hand, the significance of enzymes in preventing the accumulation of their substrates is less recognized. Here, we outline the evidence and underlying mechanisms for how many metabolites normally produced in cells are highly toxic, such as metabolites containing reactive groups (e.g., methylglyoxal, 4-hydroxynonenal, and glutaconyl-CoA), or metabolites that act as competitive analogs against other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate). Thus, if a metabolic pathway contains a toxic intermediate, then we may be able to induce accumulation and poison a cancer cell by targeting the downstream enzyme. Furthermore, this poisoning may be cancer cell selective if this pathway is overactive in a cancer cell relative to a nontransformed cell. We describe this concept as illustrated in selenocysteine metabolism and other pathways and discuss future directions in exploiting toxic metabolites to kill cancer cells.